Product Detail

1. Develop antibiotic recommendations in response to microbiologic testing results.
2. Describe clinical scenarios compelling for empiric coverage of resistant bacteria.
3. Discriminate clinical scenarios requiring initiation of antibiotics.
4. Choose appropriate risk factor–based empiric antibiotic regimens for acute infections.
5. Recognize clinical scenarios necessitating avoidance of specific antibiotics based on side effect profiles.
6. Identify clinical situations appropriate for newly approved antimicrobials.

Considerations for Successful Empiric Therapy

• Spectrum of activity for commonly used antibiotics
• Normal flora for infectious sites
• Resistance associated with common bacteria
• Pharmacodynamic influences on antibiotic dosing

Interpretation of Microbiologic Test Results 

• Gram stain results
• Culture and sensitivity results
• Minimum inhibitory concentration (MIC) evaluation
• PCR results

Antibacterial Resistance

• Trends
• Mechanisms of resistance
• Contributing factors
• Antibiotic stewardship concepts

Antibiotic Related Allergies– Penicillin and ‘Sulfa’

• Define true allergy versus side effect
• Penicillin allergy and cephalosporin cross sensitivity 
• ‘Sulfa’ allergy

SARS-CoV-2

• Clinical trial data for therapeutics
• Clinical trial data for vaccines

Skin and Soft Tissue Infections

• Streptococcus pyogenes vs. MRSA
• Evidence for antibiotic management
• IDSA treatment guidelines
• Vancomycin AUC/MIC monitoring

Pneumonia

• Evidence for pathogen etiology
• Evidence for antibiotic management
• IDSA/ATS community-acquired pneumonia treatment guidelines
• Resistance risk factors and management
• IDSA/ATS hospital- and ventilator-acquired pneumonia treatment guidelines
• New antibiotics for MDR infections

Influenza

• Evidence on vaccine timing and use in older adults
• Clinical trial data for therapeutics
• IDSA/CDC treatment guidelines

Urinary Tract Infections

• Resistance trends
• Clinical trial data for therapeutics
• Antibiotics for MDR infections

Clostridium Difficile Infection

• Risk factor literature review
• Compare antibiotic risk levels
• IDSA treatment guidelines
• Clinical trial data for therapeutics
• Probiotics prophylaxis evidence review
   

Dr. Eric Wombwell is a board-certified infectious diseases pharmacist and clinical associate professor for the Department of Pharmacy Practice and Administration at the University of Missouri – Kansas City, School of Pharmacy. Eric completed his PharmD degree at the University of Missouri Kansas City, followed by an ASHP accredited pharmacy practice residency at the Kansas City VA Medical Center. Following residency, he accepted a full-time non-tenured clinical faculty position at the University of Missouri – Kansas City, School of Pharmacy. His teaching responsibilities include infectious diseases topics throughout the curriculum. Eric also has a clinical appointment at Centerpoint Medical Center rounding with the infectious diseases consult team and supporting antimicrobial stewardship efforts at the facility.

Eric is regularly published in pharmacy and infectious diseases research and is frequently invited to deliver continuing education presentations locally and nationally to various health-professional audiences. He is recognized for excellence in teaching through various awards, including the "Missouri Pharmacist Association – UMKC Faculty Member of the Year", and the "University of Missouri – Kansas City Provost’s Award for Excellence in Teaching". Speaker Disclosures:
Financial: Eric Wombwell has an employment relationship with the University of Missouri. He receives a speaking honorarium, recording royalties, and a consulting fee from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Eric Wombwell is a member of the Society of Infectious Diseases Pharmacists, the Missouri Pharmacists Association, American Association of Colleges of Pharmacy, Infectious Diseases Society of America, and Centerpoint Medical Center.

Save time and $10 off the price of other submission methods – purchase & take the CE test online for $19.99 USD per participant. Additional processing fees apply for other submission methods (i.e. mail, fax, etc.). Please contact our Customer Service at 1-800-844-8260 for more details.

Listed below are the continuing education credit(s) currently available for this non-interactive self-study package. Please note, your state licensing board dictates whether self study is an acceptable form of continuing education. Please refer to your state rules and regulations.

Certificates of Successful Completion are available for email, download and/or printing from your online account immediately following the successful completion of the post-test/evaluation.

**Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of mental health professionals. As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice in accordance with and in compliance with your professions standards.

All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.

Inpatient and outpatient pharmacists engaged in review of antimicrobial prescription orders. In particular, those pharmacists interested in obtaining further antimicrobial expertise to aid in the care of patients with infectious diseases through optimal antimicrobial drug choice, route, dose, and duration of use.